These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 35054985)
1. A Hot Topic: Cancer Immunotherapy and Natural Killer Cells. Michel T; Ollert M; Zimmer J Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054985 [TBL] [Abstract][Full Text] [Related]
3. Engineering Natural Killer Cells for Cancer Immunotherapy. Rezvani K; Rouce R; Liu E; Shpall E Mol Ther; 2017 Aug; 25(8):1769-1781. PubMed ID: 28668320 [TBL] [Abstract][Full Text] [Related]
4. CAR-NK cell in cancer immunotherapy; A promising frontier. Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690 [TBL] [Abstract][Full Text] [Related]
5. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy. Michen S; Temme A Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137 [TBL] [Abstract][Full Text] [Related]
6. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Daher M; Rezvani K Curr Opin Immunol; 2018 Apr; 51():146-153. PubMed ID: 29605760 [TBL] [Abstract][Full Text] [Related]
7. Challenges of cancer therapy with natural killer cells. Klingemann H Cytotherapy; 2015 Mar; 17(3):245-9. PubMed ID: 25533934 [TBL] [Abstract][Full Text] [Related]
10. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities. Hu W; Wang G; Huang D; Sui M; Xu Y Front Immunol; 2019; 10():1205. PubMed ID: 31214177 [TBL] [Abstract][Full Text] [Related]
11. Natural Killer Cell-Based Cancer Immunotherapy: A Review on 10 Years Completed Clinical Trials. Suen WC; Lee WY; Leung KT; Pan XH; Li G Cancer Invest; 2018; 36(8):431-457. PubMed ID: 30325244 [TBL] [Abstract][Full Text] [Related]
15. Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies. Dong Y; Wan Z; Gao X; Yang G; Liu L Front Immunol; 2021; 12():609762. PubMed ID: 33968014 [TBL] [Abstract][Full Text] [Related]
16. Strategies to genetically engineer T cells for cancer immunotherapy. Spear TT; Nagato K; Nishimura MI Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532 [TBL] [Abstract][Full Text] [Related]
17. Editorial: Molecular Strategies Aimed to Boost NK Cell-Based Immunotherapy of Cancer. Cifaldi L; Di Santo J; Olive D Front Immunol; 2020; 11():1132. PubMed ID: 32612604 [No Abstract] [Full Text] [Related]
18. Paths taken towards NK cell-mediated immunotherapy of human cancer-a personal reflection. Ljunggren HG Scand J Immunol; 2021 Jan; 93(1):e12993. PubMed ID: 33151595 [TBL] [Abstract][Full Text] [Related]
19. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell. Lin C; Zhang J Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229 [TBL] [Abstract][Full Text] [Related]